DUBLIN--(BUSINESS WIRE)--The "RNA Therapies in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.
RNA therapies, such as miRNA, RNAi & siRNA, is an emerging class of biopharmaceutical that has immense potential in cancer medicine. Critical to the field, recent developments in delivery technologies such nanoparticle carriers and conjugation strategies have allowed RNA therapeutics to enter clinical trials in the treatment of cancer.
RNA Therapies in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your RNA therapy drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.
Keeping you In the know
Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape.
RNA Therapies in Oncology: Analytical Tool achieves this by continuously scanning development in RNA therapy and reporting:
- Deals & Collaborations
- New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
- Funding/Grants/IPOs
- Filings & Approvals
- Latest Clinical Trial Development & Results
- Newly launched clinical trials
- Conference Coverage of the world's twelve leading meetings in oncology*
- Quarterly & Annual Reporting
Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:
- Emerging Technologies
- Target Novelty
- Recent Funding
- Early & Late Stage Pipeline
- Biomarker/Companion Diagnostic Development (featured below)
- Entered Deals & Alliances
- Conference surveillance of world leading cancer meetings (featured below)
- Combination Therapy Choices (featured below)
- Outcome of Clinical Trials
- Indication Selection & Expansion Choices
-
Drug Repositioning Opportunities
Your RNA Therapies in Oncology: Analytical Tool covers more than 127 companies plus partners who are today developing 274 RNA therapy drugs where of 182 are in active development in cancer across 122 different targets.
For more information about this report visit https://www.researchandmarkets.com/research/lqslht/2018_rna?w=4
